 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- AX-158 / Artax Biopharma
TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2928;
These data suggest that selective TCR-Nck modulation represents a fundamental paradigm shift in the treatment of autoimmune diseases, one aligned with the restoration of self/non-self discrimination by the immune system.
- AX-158 / Artax Biopharma
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2889;
P1/2
There were no safety concerns following SAD and MAD administration of AX-158 in healthy subjects, with no serious or treatment-related events, and no clinically significant findings. AX-158 demonstrated excellent bioavailability, with predictable PK outcomes supporting dosing independent of food effect.
- | AX-158 / Artax Biopharma
Enrollment closed: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Aug 14, 2024
P1/2, N=31, Active, not recruiting, Sponsor: Artax Biopharma Inc
AX-158 demonstrated excellent bioavailability, with predictable PK outcomes supporting dosing independent of food effect. Recruiting --> Active, not recruiting
- || AX-158 / Artax Biopharma
Enrollment open, Phase classification: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Jan 4, 2024
P1/2, N=30, Recruiting, Sponsor: Artax Biopharma Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P2a --> P1/2
- | AX-158 / Artax Biopharma
Trial completion date, Trial initiation date, Trial primary completion date: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Sep 13, 2023
P2a, N=30, Not yet recruiting, Sponsor: Artax Biopharma Inc
Not yet recruiting --> Recruiting | Phase classification: P2a --> P1/2 Trial completion date: Aug 2024 --> Dec 2024 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Jun 2024 --> Oct 2024
- | AX-158 / Artax Biopharma
Trial initiation date: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Jun 28, 2023
P2a, N=30, Not yet recruiting, Sponsor: Artax Biopharma Inc
Trial completion date: Aug 2024 --> Dec 2024 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Jun 2024 --> Oct 2024 Initiation date: Apr 2023 --> Aug 2023
- ||| AX-158 / Artax Biopharma
Trial completion: A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses (clinicaltrials.gov) - Jun 28, 2023
P1, N=64, Completed, Sponsor: Artax Biopharma Inc
Initiation date: Apr 2023 --> Aug 2023 Active, not recruiting --> Completed
- || AX-158 / Artax Biopharma
New P2a trial: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Feb 13, 2023
P2a, N=30, Not yet recruiting, Sponsor: Artax Biopharma Inc
- || AX-158 / Artax Biopharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses (clinicaltrials.gov) - Dec 21, 2022
P1, N=64, Active, not recruiting, Sponsor: Artax Biopharma Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=104 --> 64 | Trial completion date: Aug 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Nov 2022
- ||| AX-158 / Artax Biopharma
New P1 trial: A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses (clinicaltrials.gov) - Jan 31, 2022
P1, N=104, Recruiting, Sponsor: Artax Biopharma Inc
- AX-158 / Artax Biopharma
Impacts of TCR-Nck Interaction Inhibitors on T Cell Activation Driven By Mixed Lymphocyte Reactions (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1105;
Here we show that an oral, clinic-ready second generation Nck inhibitor (AX-158) potently modulates the activation of human T cells in Mixed Lymphocyte Reactions (MLR) in vitro, suggesting that disruption of the TCR-Nck interaction is modulatory for T cell responses driven by allogeneic stimuli...MLR driven proliferative responses were not significantly impacted, suggesting that Nck inhibition leads to less activated T Cell populations to drive potential benefit. By modulating T Cell activation in response to allogeneic stimuli while sparing responses to strong foreign antigens, Nck inhibitors offer the promise of potentially treating GVHD without strong immunosuppression.